NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.31
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.35

02 Oct
2025

0.040

OPEN

$4.33

0.93%

HIGH

$4.36

563,401

LOW

$4.26

TARGET
$4.55 4.6% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 6.8 6.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 59.3% - 1.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 65.5 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx6.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx198.3 M
Book Value Per Share xxxxxxxxxxxxxxx69.1
Net Operating Cash Flow xxxxxxxxxxxxxxx44.0 M
Net Profit Margin xxxxxxxxxxxxxxx10.43 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx10.55 %
Return on Invested Capital xxxxxxxxxxxxxxx10.27 %
Return on Assets xxxxxxxxxxxxxxx7.99 %
Return on Equity xxxxxxxxxxxxxxx10.55 %
Return on Total Capital xxxxxxxxxxxxxxx8.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx35.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx162 M
Price To Book Value xxxxxxxxxxxxxxx5.86

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx50 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx131 M
Research & Development xxxxxxxxxxxxxxx32 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.2

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

27/08/2025

5

Sell

$4.10

-5.75%

Bell Potter notes Nanosonics' FY25 revenues of $198.6m was up 17% y/y, beating consensus by $4m and exceeding the top end of guidance, helped by currency benefits. EBITDA also beat consensus.

The company guided to 8-12% increase in FY25 revenues, but gross profit margin is expected to decline -200bps due to -$4m negative impact from US import tariffs. 

Coris revenue is expected to be small with commercialisation in the US delayed to FY26-end, limiting near-term upside but preserving longer-term optionality. Service & Maintenance conversion of ex-GE clients is seen as a valuable growth driver.

FY26 EBIT forecast lifted by 16% and EPS by 29%, but it is still lower vs FY25.

Sell. Target rises to $4.10 from $4.05.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.50 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.60 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

01/09/2025

1

Buy

$5.43

24.83%

Nanosonics' FY25 revenue was up 17% y/y to $198.6m, beating Canaccord Genuity's forecast and the consensus. EBITDA was up 54% y/y and still ahead of the broker's and consensus forecasts.

The broker notes service/consumables revenue rose 20% y/y, reinforcing confidence in growing annuity revenue per installed Trophon unit. The FY26 revenue guidance is for 10% growth at midpoint, and was 3% ahead of the consensus. 

Gross margins are expected to be hit by tariffs, but operating costs remain tightly managed. Coris launch strategy is largely unchanged, with gradual rollout in Europe/Australia but US launch now pushed back to FY27.

The broker lifted FY26 revenue forecast by 2.8% and FY27 by 1.6%. But EBITDA forecasts for FY26-27 are lowered by around -4.5%.

Buy. Target lifted to $5.43 from $5.15.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.84 cents.
Canaccord Genuity forecasts a full year FY27 EPS of 11.36 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia